Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

相似書籍

• Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
  由: April W. Armstrong, et al.
  出版: (2024-07-01)
• Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
  由: April W. Armstrong, et al.
  出版: (2024-06-01)
• Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
  由: April W. Armstrong, et al.
  出版: (2023-10-01)
• Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
  由: Neil J. Korman, et al.
  出版: (2024-12-01)
• Deucravacitinib in the treatment of psoriasis
  由: Tomás Estevinho, et al.
  出版: (2023-12-01)